JNJ

Johnson & Johnson is a healthcare-focused holding company whose operating companies conduct business in virtually all countries. Its core activities are research and development, manufacturing and sales of products related to human health and well-being. The Chief Executive Officer serves as chief operating decision maker, while the Executive Committee sets company strategy and priorities; U.S. and international operating-company management teams retain responsibility for strategic plans and day-to-day execution within those parameters. FY2025 revenue provides the reported scale of the consolidated enterprise.0000200406-26-000016 #0RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000

The company reports two operating segments: Innovative Medicine and MedTech. Innovative Medicine spans Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolism. Its medicines are distributed for prescription use through retailers, wholesalers, distributors, hospitals and healthcare professionals. The portfolio includes therapies across multiple myeloma, prostate cancer, lung cancer, immune-mediated inflammatory diseases, HIV/AIDS and other conditions, illustrating a model built around specialty medicines across several therapeutic franchises rather than a single disease area.0000200406-26-000016 #0

MedTech develops and manufactures products for cardiovascular care, orthopaedics, surgery and vision, supporting acute and elective procedures. Its cardiovascular offerings include electrophysiology, mechanical circulatory support, circulatory restoration and neurovascular products, frequently delivered through minimally invasive catheter-based approaches. Surgery includes instrumentation, energy devices, stapling, wound closure, biosurgery and digital and robotic technologies, while Vision includes ACUVUE contact lenses and TECNIS intraocular lenses. These products are distributed through wholesalers, hospitals and retailers and are used predominantly by healthcare professionals and clinical institutions.0000200406-26-000016 #2

Portfolio structure is set to change: in October 2025, the company announced an intention to separate its Orthopaedics business and said it would explore multiple paths to execute the transaction, targeting completion within 18 to 24 months of the announcement. Orthopaedics currently encompasses products and enabling technologies for joint reconstruction, trauma, spine and sports-related injuries. Accordingly, the planned separation could reshape the scope of the MedTech segment, although the excerpt does not specify the eventual transaction structure or outcome.0000200406-26-000016 #2

The company’s global operating footprint creates exposure to differing market conditions, distribution methods and commercial practices by country. It states that international products include many products developed in the United States and by overseas subsidiaries, but that principal markets, products and distribution methods vary by country and culture. It also identifies heightened risks in certain non-U.S. markets, where financial instability, restrictive economic policies, and political and legal-system uncertainty can influence the investment and commercial climate relative to comparable U.S. activities.0000200406-26-000016 #2Assets FY2025 = 199,210,000,000

Competition is present across all product lines, both locally and globally, with research competition—whether internally conducted or externally sourced—particularly significant. Management identifies continued investment in research, new-product development and protection of underlying intellectual property as important to success. The business also operates under increasingly stringent regulation covering drug and device safety, efficacy, manufacturing, advertising, labeling and reporting, alongside evolving privacy, cybersecurity, data-localization and AI requirements. Adverse regulatory action may materially harm financial condition or operations, and more extensive testing and documentation can increase product-introduction expense.0000200406-26-000016 #4NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000NetIncomeLoss FY2025 = 26,804,000,000

JNJ’s reported financial base combines substantial sales, earnings and internally generated cash: the filing-derived revenue, net-income and operating-cash-flow metrics are all reported for the latest fiscal year. Operating cash flow is particularly relevant to financial health because it reflects cash generated from operations rather than solely accounting earnings. The excerpts also indicate that management’s reported results rely on estimates across revenue recognition, taxes, contingencies, asset valuation, pensions and share-based compensation, so cash generation should be considered alongside the judgment-sensitive accounting underlying reported profit.0000200406-26-000016 #34RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000NetIncomeLoss FY2025 = 26,804,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000

The balance sheet carries a large asset base alongside meaningful long-term debt. The company’s liquidity framework includes access to funding from numerous banks and a recently secured credit facility, while management describes commitment fees as not material. This access supports near-term financial flexibility, although the company’s debt position and refinancing needs remain relevant to its capital structure. The filing also notes that interest on credit-line borrowings is tied to reference market rates plus applicable margins, exposing any use of the facility to prevailing interest-rate conditions.0000200406-26-000016 #34Assets FY2025 = 199,210,000,000LongTermDebtNoncurrent FY2025 = 39,438,000,000

Leverage increased during the latest year as the company issued new senior unsecured notes, principally to help fund the Intra-Cellular Therapies acquisition and for general corporate purposes. Management reported that total borrowings and net debt both rose versus the prior year, and that debt represented a higher share of total capital. The acquisition financing therefore shifted the company toward a more debt-funded capital structure, even as the company retained broad bank funding access and an operating cash-flow base. The filing does not establish whether future acquisition-related benefits will fully offset the added financing burden.0000200406-26-000016 #34LongTermDebtNoncurrent FY2025 = 39,438,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000

Working-capital and revenue quality require attention because rebates, returns, promotions, cash discounts and doubtful accounts are recorded as reductions or reserves against sales. The company recognizes product revenue when control transfers, generally extends payment terms to customers, and estimates variable consideration using contractual terms, historical experience, patient outcomes, trends and projected market conditions. The disclosed reserve activity shows that these estimates are material to the commercial model, particularly in Innovative Medicine. Changes in rebate, discount, return or market assumptions could therefore affect reported revenue, receivables and cash conversion, even without a change in underlying product volumes.0000200406-26-000016 #340000200406-26-000016 #36RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000

Legal and self-insurance exposures remain a balance-sheet and cash-flow uncertainty. JNJ accrues litigation and product-liability losses when a liability is probable and the amount can be reasonably estimated, but states that for certain matters it cannot estimate a possible loss or range beyond accrued amounts. Management highlights uncertainty around claim volumes, scientific and legal discovery, disputed facts, procedural issues, settlement prospects and the timing of payments. Consequently, reported assets, debt and operating cash flow should be evaluated with the recognition that adverse outcomes or developments could require incremental charges or cash payments not captured in presently estimable accruals.0000200406-26-000016 #360000200406-26-000016 #370000200406-26-000016 #39Assets FY2025 = 199,210,000,000LongTermDebtNoncurrent FY2025 = 39,438,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000

The company faces external pressures that could affect future earnings and cash generation: healthcare cost-containment initiatives, reimbursement and pricing regulation, changes in patient and purchaser behavior, inflation in certain markets, and challenges to intellectual-property protection. JNJ says successful generic or biosimilar challenges to key pharmaceutical products could cause substantial market-share and revenue losses and could result in non-cash impairment of associated intangible assets. It also notes that it has historically pursued responsible pricing, with its disclosed long-run U.S. net-price-increase trend below CPI; nevertheless, that policy and the broader pricing environment may constrain the ability to offset cost or volume pressures through price.0000200406-26-000016 #370000200406-26-000016 #39RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000NetIncomeLoss FY2025 = 26,804,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000Assets FY2025 = 199,210,000,000

Competitive intensity is a core earnings risk across both operating segments and geographies. Johnson & Johnson competes on cost-effectiveness, technological innovation, intellectual-property rights, product performance, perceived product advantages, pricing, availability and reimbursement. It also competes for acquisitions, collaborations and licensing opportunities, which may require significant investment, acquisition costs or onerous contractual terms. More effective or lower-cost competing products, competitors’ earlier commercialization, or their success in securing intellectual-property rights could erode sales of existing products and impair returns on prior development spending. In Innovative Medicine, loss of patent exclusivity is often followed by substantial sales declines as generic, biosimilar and other competitors enter. In MedTech, product quality, innovation, reputation and customer service are especially important; failure to introduce safe, effective and commercially differentiated advances could leave products less desirable, less economical or obsolete.0000200406-26-000016 #10

Manufacturing and supply-chain disruption could affect sales, operating performance and reputation. The company requires timely supplies of complex, high-quality components and materials, operates numerous manufacturing facilities and sources from thousands of suppliers worldwide. The filing states that it has experienced, and may again experience, unanticipated interruptions and delays in internal or external manufacturing and supply chains. This creates exposure not only to direct production shortfalls but also to potential disruption from broader operational dependencies. Climate-related physical events—including hurricanes, tornadoes, earthquakes, wildfires and flooding—may disrupt facilities and supply-chain operations. Changing water availability could limit access to sufficient high-quality water at some locations and raise operating costs. More stringent climate-related requirements could also increase sourcing, manufacturing and distribution costs, while a failure to offer climate-friendly products could contribute to market-share losses.0000200406-26-000016 #100000200406-26-000016 #20

The durability of product revenue depends materially on the company’s ability to secure and defend intellectual-property rights. Its patents and other proprietary rights relating to products and manufacturing processes are described as essential to its businesses, yet the company cannot assure adequate patent protection for new products and technologies in the United States and other important markets. Competitors routinely challenge owned or licensed rights through litigation, oppositions, interferences and inter partes review proceedings, which can be resource-intensive, prolonged and unpredictable. Third parties may also allege infringement or trade-secret misappropriation, potentially resulting in injunctions, damages or future royalty obligations. The company has faced increasing challenges from firms seeking to market generic and biosimilar versions of key pharmaceutical products before applicable patent expiry. An unsuccessful defense, or an at-risk launch, could cause the company to lose a major portion of revenue from the affected product in a very short period.0000200406-26-000016 #15

Long-term growth is exposed to execution risk in innovation, development and commercialization. The filing states that continued growth and success depend on developing new and differentiated products, technologies and services that address evolving healthcare needs. Successful development is also necessary to offset revenue losses from existing products, making pipeline execution particularly consequential when products face patent challenges or competitive entry. Delays or significant challenges in innovation, development, implementation or new indications could adversely affect long-term success. Competitive products that are more effective, less costly or launched earlier may reduce the value of the company’s development investments. Acquisitions and external collaborations add a further execution dimension: the company may be unable to fully identify acquired liabilities, integrate businesses and employees, realize expected synergies, or contain related demands on management, operations and financial resources.0000200406-26-000016 #100000200406-26-000016 #15

The planned separation of the Orthopaedics business introduces timing, cost, execution and market-value uncertainty. The company announced its intention to separate the business in October 2025 and is targeting completion within 18 to 24 months after the announcement, but completion remains subject to conditions including employee-representative consultations where required, board approval and regulatory approvals. General or financial-market disruption and issues in obtaining approvals or clearances could delay, prevent or otherwise adversely affect the transaction. The company expects significant separation expenses and cautions that it may not realize all anticipated strategic and financial benefits because those benefits depend on assumptions that may prove incorrect. It also cannot predict the effect on its share trading price; shares may be more volatile around the separation, and their market value after the transaction could be below, equal to or above the value beforehand.0000200406-26-000016 #190000200406-26-000016 #20

Financial flexibility could be pressured by a deterioration in credit quality or disruption in capital markets. The company reports investment-grade ratings from Moody’s and S&P, but rating agencies periodically reassess long- and short-term debt based on multiple factors, including factors beyond the company’s control. A downgrade, or even an announcement that ratings are under review for a downgrade, could raise borrowing costs, reduce commercial-paper market capacity, require additional collateral under derivative contracts, and negatively affect liquidity, capital position and access to capital markets. This risk is relevant to a capital structure that includes total debt and to the company’s ability to fund operations and strategic initiatives. Separately, tax-law changes can produce material expense or benefit in the period enacted, while tax authorities may adopt positions contrary to the company’s expectations, creating liabilities above established reserves.0000200406-26-000016 #190000200406-26-000016 #15LongTermDebtNoncurrent FY2025 = 39,438,000,000

The latest fiscal-year facts card reports revenue, net income and operating cash flow, alongside total assets and total debt. Taken together, these filed measures provide the current reference point for J&J’s earnings, cash generation, asset base and long-term debt position as the company navigates pricing, legal and macroeconomic developments.RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000NetIncomeLoss FY2025 = 26,804,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000Assets FY2025 = 199,210,000,000LongTermDebtNoncurrent FY2025 = 39,438,000,000

Regulatory and inflation-related developments remain active. J&J said that operations in Argentina, Venezuela, Turkey and Egypt were accounted for as highly inflationary because cumulative inflation exceeded the company’s threshold, although the company said the effect on the reported period was not material. Separately, Janssen’s challenge to the Inflation Reduction Act’s Medicare Drug Price Negotiation Program remained unresolved: in December 2025, it sought U.S. Supreme Court review after the Third Circuit affirmed a district-court ruling for the government. CMS has announced maximum fair prices for selected drugs and begun implementing the program, while J&J characterizes the business impact as uncertain.0000200406-26-000016 #38

Foreign exchange, tax and trade policy remain potential sources of earnings variability. J&J states that changes in the U.S. dollar affect the translation of foreign sales and net income, reflecting its international operating footprint. The company also flags possible changes in statutory tax rates, which could require remeasurement of jurisdiction-specific deferred tax assets and liabilities and could be material in the period enacted. It further identifies tariffs, trade-protection measures and policies favoring domestic companies or technologies as possible pressures.0000200406-26-000016 #38

The company continues to operate amid healthcare cost-containment and reimbursement pressure. J&J says that its historical U.S. weighted-average compound annual growth rate in net price increases for healthcare products was below the U.S. CPI over the cited multiyear period, while noting that government legislation and healthcare-system changes can still pressure pricing. It also identifies potential demand effects from delayed procedures, prescription rationing, fewer physician visits and reduced insurance coverage. These pressures could affect both product utilization and realized pricing.0000200406-26-000016 #370000200406-26-000016 #39

Patent and biosimilar challenges remain a material commercial risk for key pharmaceutical products. J&J notes that parties have filed abbreviated new drug applications, biosimilar applications or other challenges seeking to market competing versions before relevant patents expire. If the company does not successfully defend challenged claims, it says generic or biosimilar entry could result in substantial market-share and revenue losses for affected products and potentially lead to non-cash impairment of related intangible assets. The company also notes that competitors may launch following regulatory approval despite one or more patents being in place.0000200406-26-000016 #39

Legal contingencies remain significant, though management’s current view is that the ultimate outcome, net of accrued liabilities, is not expected to materially harm J&J’s financial position. The company has accrued matters it considers probable and reasonably estimable, but says it generally cannot estimate losses beyond accrued amounts for other probable or reasonably possible matters because of litigation-stage, factual, legal, procedural and claims-volume uncertainties. J&J cautions that resolutions or increased accruals could still materially affect results of operations and cash flows in a particular reporting period.0000200406-26-000016 #390000200406-26-000016 #40

Johnson & Johnson’s valuation context begins with a healthcare portfolio spanning two operating segments: Innovative Medicine and MedTech. Innovative Medicine addresses oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism, while MedTech serves surgery, orthopaedics, cardiovascular, and vision. This breadth provides exposure to both prescription medicines and professionally used devices, although the company states that competition is global and extends across every product line. The company also identifies continuing research investment and protection of portfolio intellectual property as important to success, making innovation output and competitive durability central considerations in assessing the earnings base.0000200406-26-000016 #22RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000

The reported financial base is substantial: FY2025 revenue, net income, and operating cash flow provide the core current-period measures for evaluating the scale of the enterprise, its accounting earnings, and internally generated cash. Total assets provide additional context for the capital employed across the group, while total debt is relevant when considering the balance-sheet obligations alongside operating cash generation. These filing-derived figures should be considered as reported rather than as a direct proxy for normalized earnings power, particularly because the company’s businesses face product, legal, and macroeconomic variables that can affect future results.0000200406-26-000016 #370000200406-26-000016 #39RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000NetIncomeLoss FY2025 = 26,804,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000Assets FY2025 = 199,210,000,000LongTermDebtNoncurrent FY2025 = 39,438,000,000

Portfolio renewal is relevant to valuation because the company reports that products introduced within the preceding five years accounted for approximately one-quarter of 2025 sales. Management also describes a significant commitment to research and development, reflecting its emphasis on creating new innovations and partnerships. At the same time, the filing makes clear that research competition is particularly significant and that substantial ongoing investment is required. Accordingly, recent-product contribution evidences meaningful new-product participation in the revenue base, but it does not eliminate execution risk around development, commercialization, competitive differentiation, or intellectual-property protection.0000200406-26-000016 #22RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000

The planned separation of the Orthopaedics business introduces a potential change in the composition of the MedTech segment. Announced in October 2025, the company intends to explore multiple paths for the separation and targets completion within 18 to 24 months of the announcement. Until the transaction structure, timing, and resulting financial profiles are determined, the current consolidated revenue, cash-flow, asset, and debt figures remain measures of the existing group rather than necessarily the eventual post-separation company. The filing does not establish the ultimate path or final terms of the planned separation.0000200406-26-000016 #22RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000Assets FY2025 = 199,210,000,000LongTermDebtNoncurrent FY2025 = 39,438,000,000

Pricing and reimbursement remain material contextual risks to the durability of reported revenue and cash generation. The company operates amid longstanding concerns over healthcare costs and states that its U.S. weighted-average net-price increases for healthcare products over 2015–2025 were below U.S. CPI. It also identifies continuing pricing pressure from cost containment and government action affecting sales, promotions, pricing, and reimbursement. Purchaser behavior—including delayed procedures, rationed prescriptions, reduced physician visits, and reduced insurance coverage—may also affect the businesses. These disclosures frame topline performance within a healthcare market where realized pricing and utilization can be constrained.0000200406-26-000016 #370000200406-26-000016 #39RevenueFromContractWithCustomerExcludingAssessedTax FY2025 = 94,193,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000

Legal, product-liability, and intellectual-property uncertainty is an important limitation when interpreting reported net income and cash flow. The company accrues legal contingencies when a loss is probable and reasonably estimable, but says it cannot estimate possible losses or ranges beyond accrued amounts for certain litigation and regulatory matters. It also notes that generic or biosimilar challenges to key pharmaceutical products could cause substantial market-share and revenue losses and may lead to impairment of associated intangible assets. Separately, valuation of long-lived assets, goodwill, and intangibles depends on management assumptions about future cash flows, which may change and could require impairment charges.0000200406-26-000016 #370000200406-26-000016 #39NetIncomeLoss FY2025 = 26,804,000,000NetCashProvidedByUsedInOperatingActivities FY2025 = 24,530,000,000Assets FY2025 = 199,210,000,000